Hims & Hers Health Inc. Stock News

Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.

Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide. The post Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch appeared first on Investor's Business Daily.

Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.

Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.

Hims & Hers (HIMS -8.84%) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today.

What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.